You are here

ASCO 2016

A Novel, Targeted Drug Yields Promising Results In Stomach And Esophageal Cancer

A Novel, Targeted Drug Yields Promising Results In Stomach And Esophageal Cancer

Forbes

esophageal cancer

Flag link:

AbbVie's Rova-T Update at ASCO: Good or Bad?

AbbVie's Rova-T Update at ASCO: Good or Bad?

Motley Fool

small cell lung cancer

Flag link:

Immunomedics' ASCO Letdown

Immunomedics' ASCO Letdown

Motley Fool

Flag link:

Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure

Biotech Buzz: ASCO Winners and Losers and Biogen's Discouraging Failure

Motley Fool

Juno Therapeutics

Flag link:

U.S. regulator says too many drugmakers chasing same cancer strategy

U.S. regulator says too many drugmakers chasing same cancer strategy

Yahoo/Reuters

Bristol-Myers Squibb

PD-1 inhibitors

Flag link:

Exelixis, Inc. Gets Some ASCO Love

Exelixis, Inc. Gets Some ASCO Love

Motley Fool

renal cell carcinoma

Flag link:

Johnson & Johnson Courting Huge Revenue Potential In Multiple Myeloma Space

Johnson & Johnson Courting Huge Revenue Potential In Multiple Myeloma Space

Seeking Alpha

Multiple Myeloma

Flag link:

Biotech Stocks: Much Ado About Nothing at ASCO?

Biotech Stocks: Much Ado About Nothing at ASCO?

Barron's

Gilead Sciences

Flag link:

Juno Therapeutics leaps on promising clinical data

Juno Therapeutics leaps on promising clinical data

CNBC

Juno Therapeutics

clinical trials

acute lymphoblastic leukemia

Flag link:

AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

AbbVie Builds Upon Robust Body of IMBRUVICA® (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

Yahoo

small lymphocytic lymphoma

Flag link:

Why ProNAi Could Be the Biggest Loser at ASCO

Why ProNAi Could Be the Biggest Loser at ASCO

24/7 Wall St

B-cell lymphoma

Flag link:

Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting

Clovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting

Yahoo

Clovis Oncology

pancreatic cancer

Flag link:

LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer

LYNPARZA (olaparib): Latest Data Suggest Potential Overall Survival Advantage in Patients with Platinum Sensitive Ovarian Cancer

Yahoo

Flag link:

Breast cancer study shows benefit to extended treatment with aromatase inhibitors

Breast cancer study shows benefit to extended treatment with aromatase inhibitors

Stat

aromatase inhibitors

Flag link:

Billionaire-backed Ganymed grabs ASCO spotlight with gastric cancer drug

Billionaire-backed Ganymed grabs ASCO spotlight with gastric cancer drug

Fierce Biotech

Flag link:

AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

AbbVie Presents Encouraging Phase 1 Data for Investigational Medicine ABT-414 as Monotherapy in Patients with an Aggressive Brain Cancer at the 2016 American Society of Clinical Oncology Annual Meeting

Yahoo

Flag link:

J&J myeloma drug, in combo regimen, delays worsening of the disease

J&J myeloma drug, in combo regimen, delays worsening of the disease

Yahoo/Reuters

Multiple Myeloma

Flag link:

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO

Yahoo

clinical trials

advanced renal cell carcinoma

Flag link:

New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting

New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting

Yahoo

Flag link:

New Roche med Tecentriq shines in study of untreated bladder cancer patients

New Roche med Tecentriq shines in study of untreated bladder cancer patients

Fierce Pharma

Flag link:

Pages